SSGJ-613 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 107 | Juvenile idiopathic arthritis | 1 |
107. Juvenile idiopathic arthritis
Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05027373 (ClinicalTrials.gov) | August 13, 2021 | 17/8/2021 | Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection | A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1ß Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects | Systemic Juvenile Idiopathic Arthritis;Periodic Fever Syndrome | Drug: SSGJ-613;Drug: Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 34 | Phase 1 | China |